Clinical Trials
23 trialsTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
LUPARPED
Fundación de investigación HM
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
NETTER-P
Advanced Accelerator Applications
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
PPGL-Pred
Rigshospitalet, Denmark
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
POLNETS_PRRT
University of Warmia and Mazury
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
DOTA-TOC
University of California, San Francisco
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
VIBRaNT
University College, London
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.